Escitalopram and amitriptyline linked to higher QTc intervals in depression trials, but no rise in early heart events
Compared with placebo: associated with increased QTc intervals (ms)
“An aggregate analysis of 139 trials (52398 participants) did not identify an association between antidepressant use and increased rates of early MACE and non-suicidal death compared with placebo (risk difference 0.01%, 95% CrI -0.01% to 0.02%).”
Where these numbers come from
“Compared with placebo, escitalopram and amitriptyline were associated with increased QTc intervals (8.7 milliseconds (ms), 95% credibility interval (CrI) 1.6 to 15.8, and 5.3 ms, 0.8 to 9.8, respectively).”
“Of 130 unique randomised controlled trials identified, 35 (27%) included individual level data (8679 participants) on QTc with placebo and 10 antidepressants (amitriptyline, bupropion, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, trazodone, venlafaxine, vortioxetine).”
“An aggregate analysis of 139 trials (52398 participants) did not identify an association between antidepressant use and increased rates of early MACE and non-suicidal death compared with placebo (risk difference 0.01%, 95% CrI -0.01% to 0.02%).”
The publication
A network meta-regression of 35 randomized trials found that escitalopram and amitriptyline were associated with increased QTc intervals of 8.7 ms and 5.3 ms, respectively, compared with placebo. However, an aggregate analysis of 139 trials involving 52,398 participants did not identify an association between antidepressant use and increased rates of early major adverse cardiovascular events or non-suicidal death.
Who the findings apply to
The study included adults aged 18 years and older with major depressive disorder diagnosed according to standardised, operationalised criteria.
The analysis focused on double blind randomised trials comparing specific antidepressants with placebo.
The primary outcome was changes in QTc Fridericia (QTcF) during the first eight weeks of treatment.
The aggregate analysis for early major adverse cardiovascular events (MACE) included data from 139 trials.
Why this matters
The findings clarify that while specific antidepressants can prolong the QTc interval, this electrical change did not translate into higher rates of early cardiovascular death or major adverse events in the studied population. This distinction is relevant for clinicians and patients weighing the cardiovascular risks of different antidepressants for major depressive disorder.
What the study found
Compared with placebo, escitalopram was associated with an increased QTc interval of 8.7 ms (95% credibility interval 1.6 to 15.8) and amitriptyline with an increase of 5.3 ms (0.8 to 9.8).
When risk factors were considered, amitriptyline and escitalopram were associated with the highest QTc prolongations at 58.8% and 21.3%, respectively.
Venlafaxine and vortioxetine were often associated with the lowest QTc intervals at 24.1% and 9.7%, respectively.
An aggregate analysis of 139 trials (52,398 participants) did not identify an association between antidepressant use and increased rates of early MACE and non-suicidal death compared with placebo (risk difference 0.01%, 95% CrI -0.01% to 0.02%).
What the result does not establish
Important variability of effects was observed, especially for escitalopram, fluoxetine, and mirtazapine.
The study relied on individual participant data from 35 trials for the QTc analysis and aggregate data for the MACE analysis.
The authors concluded that individual modifiable and non-modifiable risk factors should be considered when choosing antidepressants to support shared decision making.
Authors’ conclusion
“The effect of specific antidepressants on QTc interval differed between adults with depression. No evidence associated antidepressant use with early MACE and non-suicidal sudden death. To support shared decision making and taking into account the trade-off between benefits and harms, individual modifiable and non-modifiable risk factors should be considered when choosing antidepressants.”
Study and sources
QTc changes and early major adverse cardiovascular events associated with antidepressant treatment for major depressive disorder in adults: individual participant data network meta-regression of double blind randomised trials
Systematic review / meta-analysis · BMJ · 2026-09-23
Sources and limitations
- PubMed record PMID 42778211 (PubMed / NLM · 2026-09-28)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.